glp 1 vs glucagon Science Behind GIP and Receptor Agonists for Obesity Research | News & Announcements Clinical Focus on GLP-1 Agonists
Description
Ellis PR, Kendall CWC, Ren Y, et al
What should I do if I experience these side effects while taking this medication
A recent meta-analysis including data from SURMOUNT-1, a trial conducted in individuals with obesity, confirmed the favorable effects of tirzepatide on dyslipidemia, finding a 16 and 13.7% change from baseline in triglycerides and very low-density lipoproteins with tirzepatide 15 mg vs
In one of the most consequential healthcare deals of the year, President Trumps new drug-pricing pact with Eli Lilly and Novo Nordisk slashes the cost of blockbuster GLP-1 drugs like Wegovy and Zepbound, turning a luxury medicine into a mainstream benefitand forcing Ro, Hims, Mochi Health, and other telehealth players to rethink their most lucrative business model
In June 2023, Merck announced the results of a Phase IIa clinical trial of efinopegdutide for the treatment of NASH
